A single dose of ctx001 shows promising efficacy and safety for TDT and severe SCD

Bookmark and Share
Published: 13 Jun 2022
Views: 29
Rating:
Save
Prof Franco Locatelli - Sapienza, University of Rome, Rome, Italy

Prof Franco Locatelli presents data from the CLIMB THAL-111 and CLIMB SCD-121 studies during a press conference at the EHA 2022 meeting.

The studies aimed to evaluate the efficacy and safety of exa-cel in 44 patients with transfusion-dependent beta-thalassemia (TDT) and 31 patients with sickle cell disease (SCD).

Read the news story here